Literature DB >> 23956436

Persistence of the bacterial pathogen Granulibacter bethesdensis in chronic granulomatous disease monocytes and macrophages lacking a functional NADPH oxidase.

Jessica Chu1, Helen H Song, Kol A Zarember, Teresa A Mills, John I Gallin.   

Abstract

Granulibacter bethesdensis is a Gram-negative pathogen in patients with chronic granulomatous disease (CGD), a deficiency in the phagocyte NADPH oxidase. Repeated isolation of genetically identical strains from the same patient over years, and prolonged waxing and waning seropositivity in some subjects, raises the possibility of long-term persistence. G. bethesdensis resists killing by serum, CGD polymorphonuclear leukocytes (PMN), and antimicrobial peptides, indicating resistance to nonoxidative killing mechanisms. Although G. bethesdensis extends the survival of PMN, persistent intracellular bacterial survival might rely on longer-lived macrophages and their precursor monocytes. Therefore, we examined phagocytic killing by primary human monocytes and monocyte-derived macrophages (MDM). Cells from both normal and CGD subjects internalized G. bethesdensis similarly. G. bethesdensis stimulated superoxide production in normal monocytes, but to a lesser degree than in normal PMN. Normal but not CGD monocytes and MDM killed G. bethesdensis and required in vitro treatment with IFN-γ to maintain this killing effect. Although in vitro IFN-γ did not enhance G. bethesdensis killing in CGD monocytes, it restricted growth in proportion to CGD PMN residual superoxide production, providing a potential method to identify patients responsive to IFN-γ therapy. In IFN-γ-treated CGD MDM, G. bethesdensis persisted for the duration of the study (7 d) without decreasing viability of the host cells. These results indicate that G. bethesdensis is highly resistant to oxygen-independent microbicides of myeloid cells, requires an intact NADPH oxidase for clearance, and can persist long-term in CGD mononuclear phagocytes, most likely relating to the persistence of this microorganism in infected CGD patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23956436      PMCID: PMC3769460          DOI: 10.4049/jimmunol.1300200

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  79 in total

1.  First report of bacteremia by Asaia bogorensis, in a patient with a history of intravenous-drug abuse.

Authors:  Tamara Tuuminen; Terhi Heinäsmäki; Tuija Kerttula
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

Review 2.  The importance of penetration of antimicrobial agents into cells.

Authors:  J C Schwab; G L Mandell
Journal:  Infect Dis Clin North Am       Date:  1989-09       Impact factor: 5.982

3.  Serum bactericidal activity against Legionella pneumophila.

Authors:  J F Plouffe; M F Para; K A Fuller
Journal:  J Clin Microbiol       Date:  1985-11       Impact factor: 5.948

4.  Characterization of the electron transport system in Brucella abortus.

Authors:  R F Rest; D C Robertson
Journal:  J Bacteriol       Date:  1975-04       Impact factor: 3.490

5.  The augmented neutrophil respiratory burst in response to Escherichia coli is reduced in liver cirrhosis during infection.

Authors:  T Bruns; J Peter; S Hagel; A Herrmann; A Stallmach
Journal:  Clin Exp Immunol       Date:  2011-03-17       Impact factor: 4.330

6.  Enhanced inflammatory responses of chronic granulomatous disease leukocytes involve ROS-independent activation of NF-kappa B.

Authors:  Johan Bylund; Kelly L MacDonald; Kelly L Brown; Piotr Mydel; L Vincent Collins; Robert E W Hancock; David P Speert
Journal:  Eur J Immunol       Date:  2007-04       Impact factor: 5.532

7.  Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease (CGD).

Authors:  Joanne R Brown; David Goldblatt; Joanna Buddle; Louise Morton; Adrian J Thrasher
Journal:  J Leukoc Biol       Date:  2003-05       Impact factor: 4.962

8.  Vitamin D is required for IFN-gamma-mediated antimicrobial activity of human macrophages.

Authors:  Mario Fabri; Steffen Stenger; Dong-Min Shin; Jae-Min Yuk; Philip T Liu; Susan Realegeno; Hye-Mi Lee; Stephan R Krutzik; Mirjam Schenk; Peter A Sieling; Rosane Teles; Dennis Montoya; Shankar S Iyer; Heiko Bruns; David M Lewinsohn; Bruce W Hollis; Martin Hewison; John S Adams; Andreas Steinmeyer; Ulrich Zügel; Genhong Cheng; Eun-Kyeong Jo; Barry R Bloom; Robert L Modlin
Journal:  Sci Transl Med       Date:  2011-10-12       Impact factor: 17.956

9.  The two-domain LysX protein of Mycobacterium tuberculosis is required for production of lysinylated phosphatidylglycerol and resistance to cationic antimicrobial peptides.

Authors:  Erin Maloney; Dorota Stankowska; Jian Zhang; Marek Fol; Qi-Jian Cheng; Shichun Lun; William R Bishai; Malini Rajagopalan; Delphi Chatterjee; Murty V Madiraju
Journal:  PLoS Pathog       Date:  2009-07-31       Impact factor: 6.823

10.  Differential dependencies of monocytes and neutrophils on dectin-1, dectin-2 and complement for the recognition of fungal particles in inflammation.

Authors:  Jacqueline U McDonald; Marcela Rosas; Gordon D Brown; Simon A Jones; Philip R Taylor
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

View more
  9 in total

1.  An AAVS1-targeted minigene platform for correction of iPSCs from all five types of chronic granulomatous disease.

Authors:  Randall K Merling; Colin L Sweeney; Jessica Chu; Aaron Bodansky; Uimook Choi; Debra Long Priel; Douglas B Kuhns; Hongmei Wang; Sam Vasilevsky; Suk See De Ravin; Thomas Winkler; Cynthia E Dunbar; Jizhong Zou; Kol A Zarember; John I Gallin; Steven M Holland; Harry L Malech
Journal:  Mol Ther       Date:  2014-10-07       Impact factor: 11.454

2.  Bacterial prints in human infectious diseases.

Authors:  Oana Săndulescu
Journal:  Germs       Date:  2014-09-01

3.  Early Intracellular Trafficking of Granulibacter bethesdensis in Human Macrophages.

Authors:  Jessica Chu; Margery G Smelkinson; David W Dorward; Kol A Zarember; John I Gallin
Journal:  Infect Immun       Date:  2017-05-23       Impact factor: 3.441

4.  Simultaneous Host-Pathogen Transcriptome Analysis during Granulibacter bethesdensis Infection of Neutrophils from Healthy Subjects and Patients with Chronic Granulomatous Disease.

Authors:  David E Greenberg; Daniel E Sturdevant; Kimberly R Marshall-Batty; Jessica Chu; Anthony M Pettinato; Kimmo Virtaneva; John Lane; Bruce L Geller; Stephen F Porcella; John I Gallin; Steven M Holland; Kol A Zarember
Journal:  Infect Immun       Date:  2015-08-17       Impact factor: 3.441

5.  Fatal Meningitis in Patient with X-Linked Chronic Granulomatous Disease Caused by Virulent Granulibacter bethesdensis.

Authors:  Mafalda Rebelo; Li Ding; Ana Isabel Cordeiro; Conceição Neves; Maria João Simões; Adrian M Zelazny; Steven M Holland; João Farela Neves
Journal:  Emerg Infect Dis       Date:  2019-05       Impact factor: 6.883

6.  Variations in the Phagosomal Environment of Human Neutrophils and Mononuclear Phagocyte Subsets.

Authors:  Juliet R Foote; Amit A Patel; Simon Yona; Anthony W Segal
Journal:  Front Immunol       Date:  2019-03-01       Impact factor: 7.561

7.  Kinetic Separation of Oxidative and Non-oxidative Metabolism in Single Phagosomes from Alveolar Macrophages: Impact on Bacterial Killing.

Authors:  Vladimir Riazanski; Zihao Sui; Deborah J Nelson
Journal:  iScience       Date:  2020-11-01

8.  Methylotroph Infections and Chronic Granulomatous Disease.

Authors:  E Liana Falcone; Jennifer R Petts; Mary Beth Fasano; Bradley Ford; William M Nauseef; João Farela Neves; Maria João Simões; Millard L Tierce; M Teresa de la Morena; David E Greenberg; Christa S Zerbe; Adrian M Zelazny; Steven M Holland
Journal:  Emerg Infect Dis       Date:  2016-03       Impact factor: 6.883

9.  Granulibacter bethesdensis, a Pathogen from Patients with Chronic Granulomatous Disease, Produces a Penta-Acylated Hypostimulatory Glycero-D-talo-oct-2-ulosonic Acid-Lipid A Glycolipid (Ko-Lipid A).

Authors:  Artur Muszyński; Kol A Zarember; Christian Heiss; Joseph Shiloach; Lars J Berg; John Audley; Arina Kozyr; David E Greenberg; Steven M Holland; Harry L Malech; Parastoo Azadi; Russell W Carlson; John I Gallin
Journal:  Int J Mol Sci       Date:  2021-03-24       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.